°C : degré Celsius µm : Micromètre
ANSM : Agence Nationale de Sécurité du Médicament ADN : Acide Désoxyribonucléique
ARN : Acide Ribonucléique CI50 : Concentration inhibitrice 50
kg : Kilogramme mg : Milligramme
MGG : May Grünwald Giemsa
MIP-133 : Mannose-induced Protease 133 MMP : Metalloprotéinase Matricielle ORL : Oto-Rhino-Laryngologie PCR : Polymerase chain reaction PHMB : Polyhexamethylène Biguanide
PIM : Pourcentage d’Inhibition de Multiplication PYG : Peptone Yeast Glucose
! 1"!
ANNEXES
ANNEXE 1 : Bonnes pratiques d’usage des lentilles
Règles d’hygiène :-! Lavez, rincez et séchez vos mains (avec un essuie-main jetable) avant de poser ou de retirer vos lentilles
-! Ne jamais utiliser l’eau du robinet pour rincer les lentilles, préférer les solutions de rinçage ou les dosettes de sérum physiologique
-! Remplir et changer quotidiennement le boîtier de lentilles avec une nouvelle dose de décontaminant
-! Le soir, après utilisation, il faut nettoyer les lentilles, les rincer et les décontaminer.
-! Renouveler les étuis neufs régulièrement Règles de prudence :
-! Jeter immédiatement toute lentille abimée
-! Ne jamais dormir avec des lentilles de port quotidien sous risque de complications oculaires graves
-! Respecter la fréquence de renouvellement des lentilles indiquées sur l’ordonnance
-! Proscrire le port des lentilles en cas de baignade en piscine ou sports nautiques -! Consulter tous les ans votre ophtalmologue pour un contrôle
! 1#!
BIBLIOGRAPHIE
[1] Naginton J, Watson PG, Playfair TJ, McGill J, Jones BR, Steele AD. Amoebic
infection of the eye. Lancet 1974;2:1537—40.
[2] Awwad ST, Petroll WM, McCulley JP, Cavanagh HD. Updates in Acanthamoeba
keratitis. Eye Contact Lens 2007;33:1—8.
[3]. Siddiqui, Ruqaiyyah, and Naveed Ahmed Khan. “Biology and pathogenesis of Acanthamoeba.” Parasites & vectors vol. 5 6. 10 Jan. 2012, doi:10.1186/1756-3305- 5-6.
[4]. Castellani A: An amoeba found in culture of yeast: preliminary note. J Trop Med Hyg 1930, 160.
[5] Visvesvara, G. S. “Classification of Acanthamoeba.” Reviews of Infectious
Diseases, vol. 13, 1991, pp. S369–S372.
[6] Pussard M, Pons R. Morphologies de la paroi kystique et taxonomie du genre
Acanthamoeba [Protozoa Amoebida]. Pro- tistologica 1977;13:557—610.
[7] Stothard DR, Hay J, Schroeder-Diedrich JM, Seal DV, Byers TJ. Fluorescent oligonucleotide probes for clinical and environ- mental detection of Acanthamoeba and the T4 18S rRNA gene sequence type. J Clin Microbiol 1999;37:2687—93.
[8] Behera, Himanshu Sekhar et al. “Isolation and genotyping of Acanthamoeba spp. from Acanthamoeba meningitis/ meningoencephalitis (AME) patients in India.” Parasites & vectors vol. 9,1 442. 9 Aug. 2016, doi:10.1186/s13071-016- 1729-5.
! 1$! [9] Arnalich-Montiel, Francisco et al. “Influence of Acanthamoeba genotype on clinical course and outcomes for patients with Acanthamoeba keratitis in Spain.” Journal of
clinical microbiology vol. 52,4 (2014): 1213-6. doi:10.1128/JCM.00031-14.
[10] Bowers B, Korn ED: Cytochemical identification of phosphatase activity in the contractile vacuole of Acanthamoeba castellanii. J Cell Biol 1973, 59:784-91.
[11] Dearborn DG, Korn ED: Lipophophonoglycan of the plasma membrane of Acanthamoeba castellanii, fatty acid composition. J Biol Chem 1974, 249:3342-6.
[12] Smith FR, Korn ED: 7-Dehydrostigmasterol and ergosterol: the major sterol of an amoebae. J Lipid Res 1968, 9:405-8.
[13] Ulsamer AG, Wright PL, Wetzel MG, Korn ED: Plasma and phagosome membranes of Acanthamoeba castellanii. J Cell Biol 1971, 51:193-215.
[14] Pollard TD, Shelton E, Weihing RR, Korn ED: Ultrastructural characterization of F- actin isolated from Acanthamoeba castellanii and identification of cytoplasmic filaments as F-actin by reaction with rabbit heavy meromyosin. J Mol Biol 1970, 50:91-7.
[15] Preston TM, Richard H, Wotton RS: Locomotion and feeding of Acanthamoeba at the water-air interface of ponds. FEMS Microbiol lett 2001, 194:143-7.
[16] Burger G, Plante I, Lonergan KM, Gray MW: The mitochondrial DNA of the amoeboid protozoon, Acanthamoeba castellanii: complete sequence, gene content and genome organization. J Mol Biol 1995, 245:522-37.
[17] Chelkha et al., 2018 a phylogenetic study of acanth polyphaga draft genome
[18] Anderson IJ, Watkins RF, Samuelson J, Spencer DF, Majoros WH, Gray MW, Loftus BJ: Gene discovery in the Acanthamoeba castellanii genome. Protist 2005, 156:203-14.
[19] Band RN, Mohrlok S: The cell cycle and induced amitosis in Acanthamoeba. J Protozool 1973, 20:654-7.
! 1%! [20] Hirukawa Y, Nakato H, Izumi S, Tsuruhara T, Tomino S: Structure and expression of a cyst specific protein of Acanthamoeba castellanii. Biochim Biophys Acta 1998, 1398:47-56.
[21] Jacob Lorenzo-Morales Naveed A Khan, et al., An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite 2015;22:5.
[22] Ibrahim YW, et al., Factors affecting the epidemiology of Acanthamoeba keratitis Ophthalmic Epidemiol 2007 ; 14 : 53-60.
[23] Cursons RT, Brown TJ, Keys EA, Moriarty KM, Till D: Immunity to pathogenic free-living amoebae: role of humoral antibody. Infect Immun 1980, 29:401-7.
[24] Brindley N, Matin A, Khan NA: Acanthamoeba castellanii: high antibody prevalence in racially and ethnically diverse populations. Expe Parasitol 2009, 121:254-6.
[25] Clarke DW, et al., The pathophysiology of Acanthamoeba keratitis. Trends in Parasitology, 2006;22: 175–180.
[26] Alizadeh,H.etal.(2005)Roleofcontactlenswear,bacterialflora,and mannose-induced pathogenic protease in the pathogenesis of amoebic keratitis. Infect. Immun. 73, 1061– 1068.
[27] Clarke, D.W. et al. (2005) Failure of Acanthamoeba castellanii to produce intraocular infections. Invest. Ophthalmol. Vis. Sci. 46, 2472–2478.
[28] Alizadeh H, et al., Role of activated macrophages in Acanthamoeba keratitis. Journal of Parasitology, 2007;93: 1114–1120.
[29] Khan NA. Pathogenesis of Acanthamoeba infections. Microb Pathog 2003;34:277— 85.
! 1&! [30] Watson S, Dart JK. Acanthamoeba keratitis. In: Johnson GJ, Minassian D, Weale RA, West SK, editors. The epidemiology of eye disease. England: Arnold; 2003. p. 200— 5.
[31] Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shi- vakumar C, Srinivasan M. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol 2007;14:61—9.
[32] Acharya NR, Lietman TM, Margolis TP. Parasites on the rise: a new epidemic of
Acanthamoeba keratitis. Am J Ophthalmol 2007;144:292—3.
[33] Illingworth CD, Cook SD. Acanthamoeba keratitis. Surv Oph- thalmol 1998;42:493—508.
[34] Stehr-Green JK, Bailey TM, Visvesvara GS. The epidemiology of Acanthamoeba keratitis in the United States. Am J Ophthalmol 1989;107:331—6.
[35] Sharma S, Garg P, Rao GN. Patient characteristics, diagnosis, and treatment of non- contact lens related Acanthamoeba kera- titis. Br J Ophthalmol 2000;84:1103—8.
[36] Houang E, Lam D, Fan D, Seal D. Microbial keratitis in Hong Kong: relationship to climate, environment and contact-lens disinfection. Trans R Soc Trop Med Hyg 2001;95:361—7.
[37] Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shi- vakumar C, Srinivasan M. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol 2007;14:61—9.
[38] Kilvington S, Gray T, Dart J, Morlet N, Beeching JR, Frazer DG, et al.
Acanthamoeba keratitis: the role of domestic tap water contamination in the United
Kingdom. Invest Ophthalmol Vis Sci 2004;45:165—9.
[39] Mathers WD, Sutphin JE, Lane JA, Folberg R. Correlation bet- ween surface water contamination with amoeba and the onset of symptoms and diagnosis of amoeba-like keratitis. Br J Oph- thalmol 1998;82:1143—6.
! 1'! [40] Radford CF, Lehmann OJ, Dart JK. Acanthamoeba kera- titis: multicentre survey in England 1992—1996. National Acanthamoeba Keratitis Study Group. Br J Ophthalmol 1998;82:1387—92.
[41] Butler TK, Males JJ, Robinson LP, Wechsler AW, Sutton GL, Cheng J, et al. Six- year review of Acanthamoeba keratitis in New South Wales Australia: 1997—2002. Clin Experiment Oph- thalmol 2005;33:41—6.
[42] Fears, Alyssa C et al. “Comparative in vitro effectiveness of a novel contact lens multipurpose solution on Acanthamoeba castellanii.” Journal of ophthalmic
inflammation and infection vol. 8,1 19. 24 Oct. 2018, doi:10.1186/s12348-018-0161-8.
[43] Radford CF, Minassian DC, Dart JK. Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors. Br J Ophthalmol 2002;86:536—42.
[44] Joslin CE, Tu EY, Shoff ME, Booton GC, Fuerst PA, McMahon TT, et al. The association of contact lens solution use and Acan- thamoeba keratitis. Am J Ophthalmol 2007;144:169—80.
[45] Joslin CE, Tu EY, McMahon TT, Passaro DJ, Stayner LT, Sugar J. Epidemiological characteristics of a Chicago-area Acantha- moeba keratitis outbreak. Am J Ophthalmol 2006;142:212—7.
[46] Jeong HJ, Lee SJ, Kim JH, Xuan YH, Lee KH, Park SK, et al. Acanthamoeba: keratopathogenicity of isolates from domestic tap water in Korea. Exp Parasitol 2007;117:357—67.
[47]. Claerhout I, Goegebuer A, van Den BC, Kestelyn P. Delay in diag- nosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol 2004;242:648— 53.
[48] Bacon AS, Dart JK, Ficker LA, Matheson MM, Wright P. Acantha- moeba keratitis The value of early diagnosis. Ophthalmology 1993;100:1238—43.
! 10! [49] Clarke DW, Niederkorn JY. The immunobiology of Acanthamoeba keratitis. Microbes Infect 2006;8:1400—5.
[50] SunX,ZhangY,LiR,WangZ,LuoS,GaoM,etal.Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology 2006;113:412—6.).
[51] Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984-1992. Eye 1993;7:719—25.
[52] Tu EY, Joslin CE, Sugar J, Shoff ME, Booton GC. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology 2008;115:1998—2003.
[53] Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 2009;148:487—99.
[54] Murthy S, Hawksworth NR, Cree I. Progressive ulcerative keratitis related to the use of topical chlorhexidine gluconate [0,02 %]. Cornea 2002;21:237—9.
[55] Herz NL, Matoba AY, Wilhelmus KR. Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. Ophthalmology 2008;115:866—9.
[56] Zhang X, Sun X, Jiang C, Wang Z, Zhang Y, Deng S, et al. A new in vivo confocal microscopy prognostic factor in Acanthamoeba keratitis. J Fr Ophtalmol 2014;37:130— 7.
[57] Mathers WD, Nelson SE, Lane JL, Wilson ME, Allen RC, Folberg R. Confirmation of confocal microscopy diagnosis of Acanthamoeba keratitis using polymerase chain reaction analysis. Arch Ophthalmol 2000;118:178—83.
[58] Lehmann OJ, Green SM, Morlet N, Kilvington S, Keys MF, Mathe- son MM, et al. Polymerase chain reaction analysis of corneal epithelial and tear samples in the diagnosis of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci 1998;39:1261—5.
[59] Ikeda Y, Miyazaki D, Yakura K, Kawaguchi A, Ishikura R, Inoue Y, et al. Assessment of real-time polymerase chain reaction
! 11! [60] Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology
[61] Hay J, Kirkness CM, Seal DV, Wright P. Drug resistance and Acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy. Eye 1994;8:555—63. [62] Kilvington S, Hughes R, Byas J, Dart J. Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates. Antimicrob Agents Chemother 2002;46:2007—9.
[63] Perrine D, Chenu JP, Georges P, Lancelot JC, Saturnino C, Robba M. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agents Che- mother 1995;39:339—42.
[64] Kandori M, Inoue T, Shimabukuro M, Hayashi H, Hori Y, Maeda N, et al. Four cases of Acanthamoeba keratitis treated with phototherapeutic keratectomy. Cornea 2010;29:1199—202.
[65] Por YM, Mehta JS, Chua JL, Koh TH, Khor WB, Fong AC, et al. Acanthamoeba keratitis associated with contact lens wear in Singapore. Am J Ophthalmol 2009;148:7— 12.
[66] Gardun ̃o-Vieyra L, Gonzalez-Sanchez CR, Hernandez-Da Mota SE. Ultraviolet-a light and riboflavin therapy for Acantha- moeba keratitis: a case report. Case Rep Ophthalmol 2011;2: 291—5.
[67] Hernández-Martínez et al. (2019). Evaluation of the sensitivity to chlorhexidine, voriconazole and itraconazole of T4 genotype Acanthamoeba isolated from Mexico. Experimental Parasitology.
[68] A.J. Carrillo-Muñoz, G. Giusiano, P.A. Ezkurra, and G. Quindós. Antifungal agents : Mode of action in yeast cells. Rev Esp Quimioterap, Juin 2006.
! 12! [70] David R Haburchak, Acanthamoeba Infection Treatment & Management Updated: Aug 14, 2017, MD, MBBS, MD
[71] Bang S, Edell E, Eghrari AO, Gottsch JD. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am J Ophthalmol 2010;149:66—9.
[72] Tu EY, Joslin CE, Shoff ME. Successful treatment of chronic stromal Acanthamoeba keratitis with oral voriconazole mono- therapy. Cornea 2010;29:1066—8.
[73] Cabello-Vílchez, Alfonso Martín & Martín-Navarro, Carmen & López-Arencibia, Atteneri & Reyes Batlle, María & Sifaoui, Ines & Valladares, Basilio & Piñero, José & Lorenzo-Morales, Jacob. (2013). Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru. Parasitology research.
[74] SunadaA, KimuraK, NishiIetal. In vitro evaluations of topical agents to treat Acanthamoeba keratitis. Ophthalmology 2014; 121: 2059–65.
[75] Martin-Navarro CM, Lopez-Arencibia A, Arnalich-Montiel F et al. Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2111–7.
[76] Lovieno A, Miller D, Ledee DR et al. Cysticidal activity of antifungals against different genotypes of Acanthamoeba. Antimicrob Agents Chemother 2014; 58: 5626–8.
[77] J Ophthalmic Inflamm Infect. 2018 Oct 24;8(1):19.
[78] Eye Contact Lens. 2019 May;45(3):164-170
! 2a! [80] HILDEBRANDT C, WAGNER D, KOHLMANN T, KRAMER A. In-vitro analysis of the microbiocidal activity of 6 contact lens care solutions. BMC Infect Dis. 2012; 12: 24
! 2"!